KUALA LUMPUR, June 12 — US biotech company Moderna Inc is set to begin next month the Phase 3 clinical trial of its Covid-19 vaccine candidate with 30,000 participants.
Bloomberg reported that the test, which will be done in collaboration with the National Institute of Allergy and Infectious Diseases in the United States of America, aimed to prevent people from developing symptoms of Covid-19.
At the same time, this trial will look at the efficiency of the corronavirus vaccine to keep people from getting severe cases which require hospitalisation.
This shows that the vaccine development process for Covid-19 is going through a rapid and remarkable journey.
Moderna conducted a second-stage of its vaccine study in 600 healthy adults, Bloomberg reported.
The company also mentioned in a statement that it had already enrolled 350 people in the trial, including a cohort of 300 healthy adults 54 years and younger, and the first 50 of 300 older adults.
Besides Moderna, the University of Oxford and AstraZeneca Plc are set to begin their final-stage clinical trials of their joint Covid-19 vaccine this month. The company said that it had appointed Emergent BioSolutions Inc. to assist with the development process as well as manufacturing.
China National Biotec Group Co. or CNBG, a subsidiary of Beijing-based Sinopharm Group Co, has also taken part in the race of vaccine development, where China has instructed employees from their state-run companies to be vaccinated with two vaccines which are currently under development.